Literature DB >> 31127528

Gedunin Inhibits Oligomeric Aβ1-42-Induced Microglia Activation Via Modulation of Nrf2-NF-κB Signaling.

Sara Tom1, Anand Rane2, Aditya S Katewa2, Manish Chamoli2, Rae R Matsumoto1, Julie K Andersen2, Shankar J Chinta3,4.   

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder and the leading cause of dementia in aged populations worldwide. The deposition of toxic protein aggregates such as amyloid beta (Aβ) is a hallmark of AD, and there is growing awareness that a key driver of AD pathogenesis is the neuroinflammatory cascade triggered and sustained by these proteins. Consequently, interventions that suppress prolonged neuroinflammation represent viable therapeutic approaches for AD. In this context, we tested the natural product gedunin which is an anti-inflammatory molecule, found in the seeds of the neem tree (Azadirachta indica), whose mechanism of action remains to be fully elucidated. Using a mouse microglia cell line (IMG), we show that gedunin suppresses neuroinflammation arising from Aβ1-42 oligomer exposure. Our results demonstrate that gedunin suppresses Aβ1-42-induced NF-κB activation and its targets, including nitric oxide (NO) and IL-1β, known proinflammatory molecules. Further, we show that gedunin inhibits neuroinflammation by activating nuclear factor 2 erythroid-related factor 2 (Nrf2) and its downstream targets γ-glutamylcysteine synthetase, heme oxygenase 1, and NADPH quinone dehydrogenase 1, which are involved in quenching reactive oxygen and nitrogen species (NO) generated by NF-κB activation. Nrf2 activation appears essential for the anti-inflammatory effect because when silenced, the proinflammatory effects of Aβ1-42 are enhanced and the protective effect of gedunin against NO production is reduced. Additionally, using human neuronal cells (SH-SY5Y), we show that gedunin prevents neurotoxicity secondary to Aβ-induced microglial activation. In conclusion, our findings highlight a potential therapeutic role of gedunin in neurodegenerative diseases.

Entities:  

Keywords:  Alzheimer’s disease; Gedunin; Microglial activation; NF-κB; Neuroinflammation; Nrf2; Oligomeric amyloid beta

Mesh:

Substances:

Year:  2019        PMID: 31127528     DOI: 10.1007/s12035-019-1636-9

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  41 in total

1.  The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Marilyn S Albert; Steven T DeKosky; Dennis Dickson; Bruno Dubois; Howard H Feldman; Nick C Fox; Anthony Gamst; David M Holtzman; William J Jagust; Ronald C Petersen; Peter J Snyder; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

Review 2.  Inhibiting NF-κB activation by small molecules as a therapeutic strategy.

Authors:  Subash C Gupta; Chitra Sundaram; Simone Reuter; Bharat B Aggarwal
Journal:  Biochim Biophys Acta       Date:  2010-05-21

Review 3.  Natural Products as Sources of New Drugs from 1981 to 2014.

Authors:  David J Newman; Gordon M Cragg
Journal:  J Nat Prod       Date:  2016-02-07       Impact factor: 4.050

Review 4.  The nuclear signaling of NF-kappaB: current knowledge, new insights, and future perspectives.

Authors:  Fengyi Wan; Michael J Lenardo
Journal:  Cell Res       Date:  2009-12-08       Impact factor: 25.617

Review 5.  The therapeutic properties of Carapa guianensis.

Authors:  Maria das Graças Henriques; Carmen Penido
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 6.  Increased apoptotic cell death in sporadic and genetic Alzheimer's disease.

Authors:  Anne Eckert; Celio A Marques; Uta Keil; Katrin Schüssel; Walter E Müller
Journal:  Ann N Y Acad Sci       Date:  2003-12       Impact factor: 5.691

Review 7.  Potential therapeutic effects of the simultaneous targeting of the Nrf2 and NF-κB pathways in diabetic neuropathy.

Authors:  Veera Ganesh Yerra; Geeta Negi; Shyam S Sharma; Ashutosh Kumar
Journal:  Redox Biol       Date:  2013-08-01       Impact factor: 11.799

Review 8.  Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches.

Authors:  Inelia Morales; Leonardo Guzmán-Martínez; Cristóbal Cerda-Troncoso; Gonzalo A Farías; Ricardo B Maccioni
Journal:  Front Cell Neurosci       Date:  2014-04-22       Impact factor: 5.505

Review 9.  Herbal versus synthetic drugs; beliefs and facts.

Authors:  Ali Karimi; Maedeh Majlesi; Mahmoud Rafieian-Kopaei
Journal:  J Nephropharmacol       Date:  2015-01-01

Review 10.  Therapeutics Role of Azadirachta indica (Neem) and Their Active Constituents in Diseases Prevention and Treatment.

Authors:  Mohammad A Alzohairy
Journal:  Evid Based Complement Alternat Med       Date:  2016-03-01       Impact factor: 2.629

View more
  4 in total

Review 1.  Parkinson's disease, aging and adult neurogenesis: Wnt/β-catenin signalling as the key to unlock the mystery of endogenous brain repair.

Authors:  Bianca Marchetti; Cataldo Tirolo; Francesca L'Episcopo; Salvatore Caniglia; Nunzio Testa; Jayden A Smith; Stefano Pluchino; Maria F Serapide
Journal:  Aging Cell       Date:  2020-02-12       Impact factor: 9.304

Review 2.  Targeting Chaperone/Co-Chaperone Interactions with Small Molecules: A Novel Approach to Tackle Neurodegenerative Diseases.

Authors:  Lisha Wang; Liza Bergkvist; Rajnish Kumar; Bengt Winblad; Pavel F Pavlov
Journal:  Cells       Date:  2021-09-29       Impact factor: 6.600

3.  Therapeutic effects of total saikosaponins from Radix bupleuri against Alzheimer's disease.

Authors:  Juan Li; Bin Zou; Xiao-Yu Cheng; Xin-He Yang; Jia Li; Chun-Hui Zhao; Rui-Xia Ma; Ji-Xiang Tian; Yao Yao
Journal:  Front Pharmacol       Date:  2022-07-21       Impact factor: 5.988

Review 4.  Attenuation of Nrf2/Keap1/ARE in Alzheimer's Disease by Plant Secondary Metabolites: A Mechanistic Review.

Authors:  Sajad Fakhri; Mirko Pesce; Antonia Patruno; Seyed Zachariah Moradi; Amin Iranpanah; Mohammad Hosein Farzaei; Eduardo Sobarzo-Sánchez
Journal:  Molecules       Date:  2020-10-24       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.